Delivering timely service and evidence-informed resources to people in BC and the Yukon facing cancer and those involved in oncology care or research.
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available |
Table of contents:; History of Cancer Immunotherapy -- Section I: Basic Principles of Tumor Immunology -- Section II: Cancer Immunotherapy Targets and Classes -- Section III: Immune Function in Cancer Patients -- Section IV: Disease-Specific Treatments and Outcomes -- Section V: Regulatory Aspects …
Table of Contents:; 1. HISTORY OF IMMUNOTHERAPY -- 2. PRINCIPLES OF IMMUNOLOGY AND IMMUNOTHERAPY -- 3. CYTOKINES IN IMMUNOTHERAPY -- 4. IMMUNE CHECKPOINT INHIBITORS -- 5. BACILLUS CALMETTE-GUÉRIN - 6. ORAL IMMUNOMODULATORY AGENTS --7. ACTIVE IMMUNITY: VACCINE THERAPY -- 8. PASSIVE/ADOPTIVE IMMUNOTH…
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Library | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
Contents:; Introduction -- When to refer a patient for CAR-T cell therapy -- Optimizing the apheresis product -- CAR T cells: cell processing laboratory considerations -- Peri-CAR-T cell management -- Management of cytokine release syndrome -- Special considerations for ICU management of patients r…
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Library | Available | ||
c.1 BC Cancer Agency VIC Library | Available |
"This book presents the clinical scope of cancer immunotherapeutic agents for solid tumors and Hematologic malignancies, elaborates on the scientific details of their modes of action, and presents the impact of these agents on oncology, patients and the broader healthcare system. At present, cancer…
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VIC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Library | Available | ||
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency KEL Cancer Info Ctr | Available |
c.1 BC Cancer Agency ARHCC Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency PG Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency SUR Cancer Info Ctr | Available | ||
c.1 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency VAN Cancer Info Ctr | Available | ||
c.2 BC Cancer Agency ARHCC Cancer Info Ctr | Available |